|1.||Lacy, Martha Q: 9 articles (10/2013 - 10/2009)|
|2.||Jacques, Christian: 8 articles (10/2015 - 03/2013)|
|3.||Moreau, Philippe: 8 articles (10/2015 - 03/2013)|
|4.||Palumbo, Antonio: 7 articles (09/2015 - 10/2012)|
|5.||Anderson, Kenneth C: 7 articles (05/2015 - 09/2006)|
|6.||Corral, Laura G: 7 articles (09/2014 - 06/2003)|
|7.||Yu, Xin: 6 articles (10/2015 - 10/2013)|
|8.||Sternas, Lars: 6 articles (10/2015 - 10/2013)|
|9.||Dimopoulos, Meletios A: 6 articles (10/2015 - 01/2013)|
|10.||Tefferi, Ayalew: 6 articles (04/2014 - 09/2009)|
04/01/2013 - "Effective treatment of pomalidomide in central nervous system myelomatosis."
05/01/2015 - "A population pharmacokinetic (PPK) model of pomalidomide was developed and the influence of demographic and disease-related covariates on PPK parameters was assessed based on data from 6 clinical trials of pomalidomide (dose range, 0.5-10 mg) in healthy participants (n = 96) and patients with multiple myeloma (MM; n = 144). "
01/01/2015 - "For pomalidomide based regimens, 4 clinical studies which including 291 patients with refractory and relapsed multiple myeloma were considered eligible for inclusion. "
01/01/2015 - "Clinical studies evaluating the efffectiveness of pomalidomide based regimens on response and safety for patients with refractory and relapsed multiple myeloma were identified using a predefined search strategy. "
12/01/2014 - "Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma."
|2.||Primary Myelofibrosis (Myelosclerosis)
01/01/2015 - "Five major pomalido-mide clinical trials have been completed to date, and demonstrate tolerability and efficacy with low-dose pomalidomide (0.5 mg/day) in the treatment of myelofibrosis, and no clinical benefit of elevated dosing regimens (≥2.5 mg/day). "
02/01/2011 - "A phase-2 trial of low-dose pomalidomide in myelofibrosis."
02/01/2010 - "Phase1/-2 study of Pomalidomide in myelofibrosis."
01/01/2015 - "Profile of pomalidomide and its potential in the treatment of myelofibrosis."
11/01/2013 - "Pomalidomide at low dose is well tolerated but has modest clinical activity in myelofibrosis. "
04/01/2014 - "Moreover, compared with high-dose dexamethasone, treatment with pomalidomide plus low-dose dexamethasone significantly prolonged progression-free survival, overall survival and time to disease progression, and improved overall response rates in the intent-to-treat population. "
10/01/2013 - "They were assigned in a 2:1 ratio with a validated interactive voice and internet response system to either 28 day cycles of pomalidomide (4 mg/day on days 1-21, orally) plus low-dose dexamethasone (40 mg/day on days 1, 8, 15, and 22, orally) or high-dose dexamethasone (40 mg/day on days 1-4, 9-12, and 17-20, orally) until disease progression or unacceptable toxicity. "
09/01/2015 - "This review focuses on pomalidomide, the next generation IMiD, recently approved by the US FDA and the EMA for patients with relapsed or refractory MM who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on their last therapy. "
12/01/2014 - "This drug profile focuses on pomalidomide, the next generation IMiD, recently approved by the US FDA and the EMA for patients with relapsed or refractory MM who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on their last therapy. "
10/01/2012 - "Oral immunomodulatory drugs (IMiDs), namely thalidomide, lenalidomide and pomalidomide, interfere with several pathways important for disease progression. "
02/01/2011 - "Low-dose pomalidomide is effective in the treatment of anemia associated with JAK2V617F-positive MF; response is predicted by early drug-induced basophilia."
08/01/2012 - "Pomalidomide's good anemia response may lead to its inclusion as one of the frontline anemia therapies in MF. "
07/01/2011 - "Up to a 40% response rate on anemia has been reported with the immunomodulator, pomalidomide. "
01/01/2011 - "Pomalidomide appears to be particularly active against MF-associated anemia. "
12/01/2013 - "In parallel, phase III testing of pomalidomide is ongoing, with the goal of solidifying the role of immunomodulatory therapy in MF-associated anemia. "
|5.||Hematologic Neoplasms (Hematological Malignancy)
07/28/2011 - "Recent reports demonstrated that pomalidomide reduced or eliminated transfusion requirements in certain hematologic malignancies and induced HbF ex vivo in CD34(+) progenitor cells from healthy and SCD donors. "
01/01/2013 - "These studies delineate the mechanisms of action of pomalidomide and attest to the robust clinical activity in relapsed/refractory MM. MM is the second most common hematological malignancy in the US. "
01/15/2007 - "Moreover, this study provides new insights on the cellular pathways affected by lenalidomide and CC-4047, proposes new potential clinical uses, such as bone marrow regeneration, and suggests that the combination of lenalidomide or CC-4047 with certain HDAC inhibitors may elevate the therapeutic index in the treatment of hematologic malignancies."
06/01/2007 - "Actimid (CC-4047), another IMiD lead compound, has also undergone clinical testing in MM. Apart from hematologic malignancies, these drugs are actively under investigation in solid tumor malignancies including prostate cancer, melanoma, and gliomas, in which potent activity has been demonstrated. "
06/01/2014 - "Although thalidomide and its derivatives, lenalidomide and pomalidomide, are widely used as an essential component in the treatment of selected hematologic neoplasms including multiple myeloma, the precise mechanisms by which these agents exert anti-tumor effects have yet to be clarified. "
|1.||lenalidomide (CC 5013)
|7.||Proteasome Endopeptidase Complex (Proteasome)
|9.||Hydroxyproline (4 Hydroxyproline)
|1.||Drug Therapy (Chemotherapy)
|3.||Stem Cell Transplantation